The carrying amount of goodwill at September 30, 2020 and March 31, 2020 was $78.1 million and $32.0 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, in May 2005, ECP in July 2014 and Breethe, Inc. in April 2020. The carrying value of goodwill and the change in the balance for the six months ended September 30, 2020 are as follows:

	(in $000's)
Balance, March 31, 2020	$	31,969
Breethe, Inc. acquisition		44,048
Foreign currency translation impact		2,105
Balance, September 30, 2020	$	78,122

The Company evaluates goodwill at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on goodwill.

The carrying amount of IPR&D assets at September 30, 2020 and March 31, 2020 was $42.9 million and $14.9 million, respectively, and was recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014 and Breethe, Inc, in April 2020.

	September 30, 2020		March 31, 2020
	(in $000's)
ECP	$	15,895	$	14,913
Breethe, Inc.		27,000		—
	$	42,895	$	14,913

The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for the future Impella ECP^TM expandable catheter pump and the future Abiomed Breethe OXY-1 System were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used discount rates ranging from 15% to 21% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2020 are as follows:

	(in $000's)
Balance, March 31, 2020	$	14,913
Breethe, Inc. acquisition		27,000
Foreign currency translation impact		982
Balance, September 30, 2020	$	42,895

The Company evaluates IPR&D assets at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on IPR&D assets.

	September 30, 2020		March 31, 2020
	(in $000's)
Investment in Shockwave Medical	$	22,494	$	55,704
Other investments		39,041		38,741
Operating lease right of use asset (Note 8)		11,021		11,760
Cross currency swap (Note 6)		—		3,786
Other intangible assets and other assets		10,038		7,664
Total other assets	$	82,594	$	117,655

The fair value of the Company’s investment in Shockwave Medical, a publicly-traded medical device company, was $22.5 million and $55.7 million as of September 30, 2020 and March 31, 2020, respectively. During the three and six months ended September 30, 2020, amounts recorded in other income (expense), net of tax, were gains of $8.2 million and $26.2 million, respectively. During the three and six months ended September 30, 2019, amounts recorded in other income (expense), net of tax, were losses of $34.5 million and $4.5 million, respectively. During the quarter ended September 30, 2020, the Company sold approximately 1.4 million of its shares for cash proceeds of $67.9 million and total realized gain of $47.3 million. The Company held 0.3 million shares of Shockwave Medical at September 30, 2020.

The carrying value of the Company’s portfolio of other investments and the change in the balance for the three and six months ended September 30, 2020 and 2019 are as follows:

	For the Three Months Ended September 30,					For the Six Months Ended September 30,
		2020			2019		2020			2019
	(in $000's)
Beginning balance	$	38,741		$	26,584		38,741			24,584
Additions		1,100			5,000		3,100			7,000
Reclassification		—			—		(2,000	)		—
Impairment		(800	)		—		(800	)		—
Ending balance	$	39,041		$	31,584	$	39,041		$	31,584

During the three and six months ended September 30, 2020, the Company recorded an impairment loss of $0.8 million in other (expense) income relating to certain of the Company’s investment in other private medical device companies.

Included within other intangible assets and other is $4.1 million related to license manufacturing rights to certain technology from third parties. These intangible assets are classified with other assets in the Company’s consolidated balance sheet and are amortized over their useful life of 15 years.